Dr.Reddy's Laboratories Ltd

BSE: 500124 NSE: DRREDDY
Dr.Reddy's Laboratories Ltd - pharma in Hyderabad, Telangana, India. FY 2026 financials & compliance.
CIN L85195TG1984PLC004507 Incorporated 24 February 1984 ROC Hyderabad HQ Hyderabad, Telangana, India
Active Listed - NSE: DRREDDY · BSE: 500124 Public Limited Company pharma Fortune India 500 · #83 India's Most Valuable Nifty 50
Data last updated
Market Cap
₹1,03,876 Cr
DRREDDY · NSE
Share Price
₹1,239.00
-0.44% today
Revenue
₹33,700 Cr
FY 2025-26 · +3.2% YoY
EBITDA
₹6,454 Cr
Margin 19.1%
Net Profit
₹4,007 Cr
FY 2025-26 · -27.8% YoY
P/E (TTM)
32.2x
P/B 2.7x
ROE
11.6%
ROCE 13.7%
Debt / Equity
0.17
Interest cover 8.5x

About Dr.Reddy's Laboratories Ltd

Data last updated:

Dr.Reddy's Laboratories Ltd is a public limited company based in Hyderabad, Telangana, India. It operates in the drug formulation and development segment of the pharmaceuticals sector. It was incorporated on 24 February 1984 and has been in existence for over 42 years.

Dr.Reddy's Laboratories is ranked #83 on the Fortune India 500 (2025). It is part of the Nifty 50, Nifty 500 and BSE 500 indices. Its director K Satish Reddy and family are #223 among India's richest people (2026).

The company is registered with the Registrar of Companies (ROC), Hyderabad, under CIN L85195TG1984PLC004507. Its GSTIN is 36AAACD7999Q1ZL (Telangana). The company holds 35 GST registrations, of which 24 are active. Its shares are listed on BSE: 500124 and NSE: DRREDDY.

The company has an authorised share capital of ₹145 Cr and a paid-up capital of ₹83.47 Cr. It was formerly known as Dr.Reddy'S Laboratories P Ltd. It is led by directors including Venkateswara Prasad Gunupati (Managing Director) and Satish Reddy Kallam (Whole-Time Director).

Its last annual general meeting (AGM) was held on 23 July 2026, and its latest financial statements are for the year ended 31 March 2026. The registered office is at 8 – 2 – 337 Road No. 3 Banjara Hills, Hyderabad, Telangana, India – 500034.

As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹33,700 Cr, a growth of 3.2% compared to the previous year. For the same year it recorded a net profit of ₹4,007.16 Cr (net margin 11.9%) and EBITDA of ₹6,453.5 Cr (EBITDA margin 19.1%). The net worth stands at ₹37,892 Cr (up 12.9% YoY). Total assets are valued at ₹46,343 Cr (up 19.2% YoY).

The company has about 7,985 employees on its provident fund (EPFO) records. Its group structure includes 9 subsidiaries and 1 joint venture.

The company is associated with 3 brands: Aurigene, Studio 5b and Dr. Reddy's Laboratories. As per MCA filings, the company has open charges of ₹34.23 Cr and satisfied charges of ₹586.71 Cr on record. Court records list 730 cases involving the company, including 485 filed by the company and 247 filed against it; 192 cases are pending. The company has 72 deals on record (61 market trades, 4 secondary share transfers, 4 acquisitions), with disclosed funding of ₹630 Cr; the latest was in September 2025. Its 6 peer companies in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products) are compared by revenue, 1 larger and 5 smaller; the largest is Sun Pharmaceutical Industries Limited with revenue of ₹54,543 Cr. The company has 102 MSME Form 1 returns on record between 2008 and 2024, listing 879 overdue payments to 93 micro and small suppliers.

The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website drreddys.com.

Company Details of Dr.Reddy's Laboratories Ltd
CIN L85195TG1984PLC004507
Registration Number 004507
Incorporation Date 24 February 1984
ROC Hyderabad
Listing Status Listed (BSE: 500124, NSE: DRREDDY)
Company Status Active
Date of Last AGM 23 July 2026
Date of Balance Sheet 31 March 2026
Compliance Status Active Compliant

CIN History

Dr.Reddy's Laboratories has one previous CIN (Corporate Identification Number): L85195AP1984PLC004507. The current CIN is L85195TG1984PLC004507, which is the unique identifier assigned by the Registrar of Companies.

CINStatus
L85195TG1984PLC004507Current
L85195AP1984PLC004507Previous
Key People
Erez Israeli Ceo Venkateswara Prasad Gunupati Managing Director Satish Reddy Kallam Whole-Time Director

Recognitions & Rankings of Dr.Reddy's Laboratories

Fortune India 500 2025 edition
Rank#83
Total income
₹34,308 Cr
Profit
₹5,655 Cr
Last year #85
India's Most Valuable Companies 2025 edition · Source: Hurun India
Valuation
₹1,10,420 Cr
2024 #61 2023 #47 2022 #54
Stock market indices
Nifty 50 Nifty 500 BSE 500
Contact Details
  • Email
    Locked
  • Telephone
    Locked
  • Website
    drreddys.com
  • Social Media
  • Registered Address
    8 – 2 – 337 Road No. 3 Banjara Hills, Hyderabad, Telangana, India – 500034
  • Industry
    Pharma, Drug Formulation & Development
Comprehensive company report
Dr.Reddy's Laboratories Ltd - one report that includes everything
  • Company details, directors and signatories
  • Historical financials and ratios
  • Shareholding pattern and group structure
  • Charges with holder and property details
  • Legal cases, compliance and MCA filings
  • One PDF report, delivered after checkout
₹799 ₹999 20% off excluding 18% GST
Secure checkout · GST invoice included

Unlock the full report on Dr.Reddy's Laboratories

Financials, compliance, directors, charges, ownership and filings for Dr.Reddy's Laboratories Ltd in one report.

Financials from 2015 Directors & ownership Charges & compliance

Associated Brands

Dr.Reddy's Laboratories operates multiple associated brands including Aurigene, Studio 5b, and Dr. Reddy's Laboratories. Each brand links to its own profile.

BrandDescriptionWebsite
Aurigene
Discovers and develops novel oncology therapeutics via research collaborations.aurigene.com
Dr. Reddy's Laboratories
Innovative medicines are developed and manufactured globally by the company.drreddys.com
Studio 5b
Design of people-centric healthcare solutions globally.studio-5b.com

Business Activity

The main business activity of Dr.Reddy's Laboratories is manufacturing. In detail, this covers chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products.

Main Activity Group CodeDescription of Main ActivityBusiness Activity CodeDescription of Business ActivityTurnover Percentage
CManufacturingC6Chemical and chemical products, pharmaceuticals, medicinal chemical and botanical productsLocked
Premium access

Business activity turnover details

Turnover share and past changes in activity are in the company report.

  • Turnover contribution
  • Historical classifications
  • Filing-level activity changes

Financials of Dr.Reddy's Laboratories Ltd

FY 2025-26 filings available

Dr.Reddy's Laboratories Ltd reported revenue of ₹33,700 Cr (up 3.2% YoY) for FY 2025-26.

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹33,700 Cr
+3.2% YoY
EBITDA
₹6,454 Cr
-24.5% YoY
Profit After Tax
₹4,007 Cr
-27.8% YoY
Net Worth
₹37,892 Cr
+12.9% YoY
Total Assets
₹46,343 Cr
+19.2% YoY
Total Debt
₹7,734 Cr
+65.4% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue33,70032,64428,01124,67021,54519,04817,517
Revenue growth+3.2%+16.5%+13.5%+14.5%+13.1%+8.7%-
EBITDA6,4548,5477,9336,3493,7683,8702,470
EBITDA margin+19.2%+26.2%+28.3%+25.7%+17.5%+20.3%+14.1%
Profit before tax5,3937,6807,2016,0483,0612,8841,886
Net profit4,0075,5485,5124,5982,1111,9542,030
Net profit margin+11.9%+17.0%+19.7%+18.6%+9.8%+10.3%+11.6%
EPS (₹)50.2567.81334.41270.55131.16117.28121.90
Balance sheet
Total assets46,34338,87930,59524,85622,79020,88518,089
Net worth37,89233,55028,25523,28619,21217,64215,599
Total debt7,7344,6772,0021,3473,3843,0312,210
Cash & bank3,3492,4601,7281,7302,4192,079205
Net working capital16,12212,54412,2158,6238,8097,4695,096
Cash flow
Cash from operations5,6744,6434,5435,8882,8113,5702,984
Cash from investing(6,425)(5,785)(4,034)(4,109)(2,565)(2,255)(495)
Cash from financing8291,891(376)(2,686)(242)(29.80)(2,516)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,1007,5468,7538,8288,5728,5288,3818,038
Revenue growth (YoY)-5.5%-11.5%+4.4%+9.8%+11.4%---
Other income356480271330290528154314
EBITDA8603821,8882,0102,1741,9982,2732,076
EBITDA margin+10.7%+5.1%+21.6%+22.8%+25.4%+23.5%+27.2%+25.9%
Depreciation537557521505476455471397
Interest12610694.4090.7083.0065.6081.7075.70
Profit before tax5532001,5431,7451,9052,0051,8741,917
Tax118(21.60)354408495418470576
Net profit4362211,1901,3371,4101,5871,4041,342
EPS (₹)5.332.6514.5216.1817.0219.1016.9475.25
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue20,53323,11519,48416,96214,40513,34911,850
Revenue growth-11.2%+18.6%+14.9%+17.8%+7.9%+12.7%-
EBITDA3,9177,3825,9264,2152,5943,1372,870
EBITDA margin+19.1%+31.9%+30.4%+24.9%+18.0%+23.5%+24.2%
Profit before tax4,2517,2365,7913,8662,2243,0562,776
Net profit3,0635,3814,2842,6291,6291,8492,949
Net profit margin+14.9%+23.3%+22.0%+15.5%+11.3%+13.9%+24.9%
EPS (₹)38.5664.14260.31156.8397.55131.39176.76
Balance sheet
Total assets37,35732,54025,14820,61820,63618,26616,733
Net worth31,36628,85724,24120,47418,33616,98415,192
Total debt5,7373,49379350.802,2051,2141,457
Cash & bank1,9589771,2176462,0301,64639.20
Net working capital9,6348,3858,9035,0737,7206,3245,245
Cash flow
Cash from operations4,6604,2253,4505,0531,3393,5141,839
Cash from investing(5,760)(5,697)(3,429)(3,403)(1,990)(1,454)(1,689)
Cash from financing1,1171,59168.10(2,697)506(794)(224)
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,1373,8224,2834,6197,8105,5635,0156,696
Revenue growth (YoY)-34.2%-31.3%-14.6%-31.0%+33.7%---
Other income440567360364398414235208
Total expenses4,6894,3224,1834,1383,9724,1203,8233,975
EBITDA447(500)99.604803,8371,4431,1922,722
EBITDA margin+8.7%-13.1%+2.3%+10.4%+49.3%+26.0%+23.9%+40.7%
Depreciation318318314295280264265260
Interest73.1054.3041.4033.4019.2031.1043.3028.40
Profit before tax497(306)1045163,9361,5621,1192,641
Tax92.30(86.10)13.60129975361270759

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 22 Oct 2026
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue8,1007,5468,7538,8288,5728,5288,3818,038
Revenue growth (YoY)-5.5%-11.5%+4.4%+9.8%+11.4%---
Other income356480271330290528154314
EBITDA8603821,8882,0102,1741,9982,2732,076
EBITDA margin+10.7%+5.1%+21.6%+22.8%+25.4%+23.5%+27.2%+25.9%
Depreciation537557521505476455471397
Interest12610694.4090.7083.0065.6081.7075.70
Profit before tax5532001,5431,7451,9052,0051,8741,917
Tax118(21.60)354408495418470576
Net profit4362211,1901,3371,4101,5871,4041,342
EPS (₹)5.332.6514.5216.1817.0219.1016.9475.25
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue33,70032,64428,01124,67021,54519,04817,517
Revenue growth+3.2%+16.5%+13.5%+14.5%+13.1%+8.7%-
Other income1,3721,1199091,092555339677
Total expenses27,24724,09720,07818,32117,77815,17815,047
Employee cost5,9915,5805,0304,6473,8863,6303,380
EBITDA6,4548,5477,9336,3493,7683,8702,470
EBITDA margin+19.2%+26.2%+28.3%+25.7%+17.5%+20.3%+14.1%
Depreciation2,0591,7041,4701,2501,1651,2291,163
Interest37428317114395.8097.0098.30
Profit before tax5,3937,6807,2016,0483,0612,8841,886
Tax1,2351,9541,6231,541879932(140)
Net profit4,0075,5485,5124,5982,1111,9542,030
Net profit margin+11.9%+17.0%+19.7%+18.6%+9.8%+10.3%+11.6%
EPS (₹)50.2567.81334.41270.55131.16117.28121.90
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital83.5083.4083.4083.3083.2083.2083.10
Reserves & surplus37,99033,69328,17123,33019,28917,75515,616
Shareholders' funds (net worth)37,89233,55028,25523,28619,21217,64215,599
Minority interest3393780.000.000.000.000.00
Secured loans0.000.000.000.000.000.00179
Unsecured loans7,7344,6772,0021,3473,3843,0312,032
Total debt7,7344,6772,0021,3473,3843,0312,210
Total liabilities46,34338,87930,59524,85622,79020,88518,089
Assets
Gross block43,85436,76028,06225,56723,09618,55616,108
Net block22,06318,22610,4269,2198,1228,2066,850
Capital work in progress1,4602,4661,4191,0301,2931,5651,535
Investments5,2854,0514,9304,9862,6162,2122,678
Inventories7,6537,1086,3554,8675,0884,5413,507
Sundry debtors10,1239,0428,0307,2486,6764,9645,028
Cash & bank balances3,3492,4601,7281,7302,4192,079205
Loans & advances5,2303,0774,2882,1301,5811,5881,491
Total current assets26,35621,68720,40015,97615,76513,17210,230
Total current liabilities10,2349,1448,1857,3536,9565,7035,134
Net working capital16,12212,54412,2158,6238,8097,4695,096
Total assets46,34338,87930,59524,85622,79020,88518,089
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash1,4597115781,4851,482196223
Net cash from operating activities5,6744,6434,5435,8882,8113,5702,984
Net cash from investing activities(6,425)(5,785)(4,034)(4,109)(2,565)(2,255)(495)
Net cash from financing activities8291,891(376)(2,686)(242)(29.80)(2,516)
Net change in cash77.50749133(907)3.201,286(26.60)
Closing cash3,3492,4601,7281,7302,4192,079205
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+3.2%+16.5%+13.5%+14.5%+13.1%+8.7%-
EBITDA growth-24.5%+7.7%+25.0%+68.5%-2.6%+56.7%-
PBT growth-29.8%+6.6%+19.1%+97.6%+6.2%+52.9%-19.3%
Net income growth-27.8%+0.7%+19.9%+117.8%+8.0%-3.7%-
Revenue CAGR (3Y)+11.0%+14.9%+13.7%+12.1%+11.7%+10.1%+7.3%
EBITDA CAGR (3Y)+0.6%+31.4%+27.0%+37.0%+5.8%+18.1%-0.0%
Profitability & leverage
Net income margin+12.3%+17.5%+19.9%+18.3%+10.1%+10.3%+11.6%
Return on capital employed+13.7%+23.1%+26.6%+26.0%+14.5%+15.3%+11.0%
Return on net worth+11.6%+18.5%+21.6%+21.2%+11.8%+11.7%+13.7%
Debt / equity0.170.110.060.110.170.160.20
Long-term debt / equity0.030.020.010.020.030.020.08
Interest cover8.514.132.652.803.683.677.52
Efficiency & per share
Fixed asset turnover0.841.011.041.011.031.101.13
Inventory turnover4.574.854.994.964.474.735.10
Debtors turnover3.523.823.673.543.703.813.89
EPS (₹)50.2567.81334.41270.55131.16117.28121.90
Dividend per share (₹)8.008.0040.0040.0030.0025.0025.00
Book value per share (₹)455.96404.991,693.931,405.341,164.211,072.02944.61
ParticularsJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024
Revenue5,1373,8224,2834,6197,8105,5635,0156,696
Revenue growth (YoY)-34.2%-31.3%-14.6%-31.0%+33.7%---
Other income440567360364398414235208
Total expenses4,6894,3224,1834,1383,9724,1203,8233,975
EBITDA447(500)99.604803,8371,4431,1922,722
EBITDA margin+8.7%-13.1%+2.3%+10.4%+49.3%+26.0%+23.9%+40.7%
Depreciation318318314295280264265260
Interest73.1054.3041.4033.4019.2031.1043.3028.40
Profit before tax497(306)1045163,9361,5621,1192,641
Tax92.30(86.10)13.60129975361270759
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue20,53323,11519,48416,96214,40513,34911,850
Revenue growth-11.2%+18.6%+14.9%+17.8%+7.9%+12.7%-
Other income1,6901,003862591482801743
Total expenses16,61515,73413,55712,74811,81110,2128,981
Employee cost3,5503,2883,0862,8332,4352,2702,030
EBITDA3,9177,3825,9264,2152,5943,1372,870
EBITDA margin+19.1%+31.9%+30.4%+24.9%+18.0%+23.5%+24.2%
Depreciation1,2071,039976923814835789
Interest14811021.8016.9038.0046.7047.80
Profit before tax4,2517,2365,7913,8662,2243,0562,776
Tax1,0321,8861,4491,253601870(162)
Net profit3,0635,3814,2842,6291,6291,8492,949
Net profit margin+14.9%+23.3%+22.0%+15.5%+11.3%+13.9%+24.9%
EPS (₹)38.5664.14260.31156.8397.55131.39176.76
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital83.5083.4083.4083.3083.2083.2083.10
Reserves & surplus31,46429,00024,15720,51818,41317,09715,209
Shareholders' funds (net worth)31,36628,85724,24120,47418,33616,98415,192
Secured loans0.000.000.000.000.000.0019.30
Unsecured loans5,7373,49379350.802,2051,2141,438
Total debt5,7373,49379350.802,2051,2141,457
Total liabilities37,35732,54025,14820,61820,63618,26616,733
Assets
Gross block21,34417,71516,29715,13713,34912,34510,216
Net block10,7308,2327,5897,1956,1505,8444,434
Capital work in progress1,3692,1971,2119241,200901412
Investments15,59513,1947,3217,4404,9374,6495,486
Inventories4,9564,5764,0193,0433,3482,8202,190
Sundry debtors4,1195,9594,6244,2894,9454,0804,639
Cash & bank balances1,9589771,2176462,0301,64639.20
Loans & advances4,2582,1083,8381,5131,2551,1411,120
Total current assets15,29013,62013,6989,49011,5799,6877,988
Total current liabilities5,6565,2354,7954,4183,8593,3642,743
Net working capital9,6348,3858,9035,0737,7206,3245,245
Total assets37,35732,54025,14820,61820,63618,26616,733
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash3202011121,1601,30539.10113
Net cash from operating activities4,6604,2253,4505,0531,3393,5141,839
Net cash from investing activities(5,760)(5,697)(3,429)(3,403)(1,990)(1,454)(1,689)
Net cash from financing activities1,1171,59168.10(2,697)506(794)(224)
Net change in cash17.8011889.10(1,047)(146)1,266(74.10)
Closing cash1,9589771,2176462,0301,64639.20
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth-11.2%+18.6%+14.9%+17.8%+7.9%+12.7%-
EBITDA growth-46.9%+24.6%+40.6%+62.5%-17.3%+9.3%-
PBT growth-41.3%+24.9%+49.8%+73.9%-27.2%+10.1%+63.2%
Net income growth-43.1%+25.6%+63.0%+61.4%-11.9%-37.3%-
Revenue CAGR (3Y)+6.6%+17.1%+13.4%+12.7%+10.7%+12.6%+6.8%
EBITDA CAGR (3Y)-2.4%+41.7%+23.6%+13.7%+4.1%+33.1%+18.0%
Profitability & leverage
Net income margin+15.7%+23.1%+22.3%+15.4%+11.3%+16.4%+24.8%
Return on capital employed+12.6%+25.5%+25.4%+18.8%+11.6%+15.0%+18.5%
Return on net worth+10.7%+20.2%+19.4%+13.5%+9.2%+11.5%+21.1%
Debt / equity0.150.080.020.060.100.080.09
Long-term debt / equity0.010.000.000.000.000.000.01
Interest cover5.471.730.440.512.142.032.30
Efficiency & per share
Fixed asset turnover1.051.361.241.191.121.181.19
Inventory turnover4.315.385.525.314.675.335.63
Debtors turnover4.074.374.373.673.193.062.84
EPS (₹)38.5664.14260.31156.8397.55131.39176.76
Dividend per share (₹)8.008.0040.0040.0030.0025.0025.00
Book value per share (₹)377.81348.721,453.291,236.561,111.561,032.48920.13
Want more history and ratios?
You're viewing the latest exchange-filed financials for Dr.Reddy's Laboratories Ltd. The full report adds 10+ years of line-item history, 20+ ratios, peer benchmarks and a downloadable PDF.
10+ years of history 20+ ratios & benchmarks Downloadable PDF

Board of Directors and KMP of Dr.Reddy's Laboratories Ltd

Dr.Reddy's Laboratories Ltd currently reports 11 directors and 2 key managerial personnel. 21 former directors have served the organization.

Current Directors and KMP
NameDesignationAppointment DateTenureStatus
Kodumudi Pranatharthiharan Krishnan
Also directs: Tata Consumer Products Limited, Asrec (India) Limited, Helios Trustee Private Limited and 3 more
Director07 Jan 20224 Years 9 MonthsCurrent
Venkatanarasimham Mannam
Also directs: Idea2enterprises (India) Private Limited, Dr. Reddy's Formulations Limited, DRL Impex Limited and 5 more
Cfo01 Aug 20242 Years 2 MonthsCurrent
Leo Puri
Also directs: Fortis Healthcare Limited
Director25 Oct 20187 Years 11 MonthsCurrent
Erez Israeli
Also directs: Aurigene Pharmaceutical Services Limited
Ceo01 Aug 20197 Years 2 MonthsCurrent
Arun Madhavan Kumar
Also directs: Celesta India Aif LLP, Celesta India Aif Managers LLP, Agnikul Cosmos Private Limited
Director01 Aug 20224 Years 2 MonthsCurrent
Satish Reddy Kallam
Also directs: Aurigene Oncology Limited, Greenpark Hotels and Resorts Limited, Stamlo Industries Limited and 5 more
Whole-Time Director18 Jan 199333 Years 9 MonthsCurrent
Showing 6 of 13 current directors and KMP. View all directors and KMP

Peer Comparison

Dr.Reddy's Laboratories Ltd is compared with the companies closest to it by revenue in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products). Net profit, margin and employee counts of each company are in the company report.

CompanyRevenueNet profitMarginGrowth (1 yr)EmployeesLocation
Sun Pharmaceutical Industries Limited Listed₹54,543 Cr (FY 2025)••••••••9.0%••••Vadodara, Gujarat, India
Dr.Reddy's Laboratories Ltd this company₹33,700 Cr (FY 2026)••••••••3.2%••••Hyderabad, Telangana, India
Aurobindo Pharma Ltd Listed₹32,346 Cr (FY 2025)••••••••9.0%••••Hyderabad, Telangana, India
Cipla Limited Listed₹28,409 Cr (FY 2025)••••••••7.0%••••Mumbai, Maharashtra, India
Zydus Lifesciences Limited Listed₹23,511 Cr (FY 2025)••••••••19.0%••••Ahmedabad, Gujarat, India
Lupin Limited Listed₹22,904 Cr (FY 2025)••••••••14.0%••••Mumbai, Maharashtra, India
Intas Pharmaceuticals Limited₹21,241 Cr (FY 2025)••••••••7.0%••••Ahmedabad, Gujarat, India

Peers are the companies nearest to Dr.Reddy's Laboratories by revenue, above and below it, in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products), from the latest filed financials of each company. Net profit, margin and employee counts of each peer are in the company report.

Auditor Details

Dr.Reddy's Laboratories Ltd is audited by S.R. Batliboi & Associates LLP for the financial year 2024.

NameStatusAppointment DateCessation Date
S.R. Batliboi & Associates LLPLockedLockedLocked

Complete auditor history: available in the company report

Shareholding Pattern

Shareholding for the quarter ended Sep 2026: promoters hold 26.60%, foreign institutional investors hold 20.70%, domestic institutional investors hold 43.10% and retail and other public shareholders hold 9.60%.

Promoters: 26.60%DII (Domestic Institutional): 43.10%FII (Foreign Institutional): 20.70%Retail & Others: 9.60%
Sep 2026
QUARTER
26.60% Promoters
43.10% DII (Domestic Institutional)
20.70% FII (Foreign Institutional)
9.60% Retail & Others
Promoter holding - history
Now 26.60% · Sep 2026High 26.60% · Dec 2025Low 26.60% · Dec 2025
25%25.8%26.5%27.3%28%Dec 2025Mar 2026Jun 2026Sep 2026Dec 2025: 26.60%Mar 2026: 26.60%Jun 2026: 26.60%Sep 2026: 26.60%26.60%26.60%
Shareholding trend - last 6 quarters
Sep 2026Jun 2026Mar 2026Dec 2025
Promoters26.60%26.60%26.60%26.60%
Public73.40%73.40%73.40%73.40%

Charges & Borrowings

Open charges
₹34.23 Cr
Satisfied charges
₹586.71 Cr
Breakdown by lending institutions
Globaltrust Bank Ltd₹20.00 Cr
Global Trust Bank Ltd₹7.60 Cr
Global Tust Bank Ltd₹5.50 Cr
Industrial Finance Corp. of India₹0.45 Cr
Andhra Bank₹0.25 Cr
Others₹0.43 Cr
Latest charge details
DateLenderAmountStatus
02 Aug 1996Globaltrust Bank Ltd₹10 CrOpen
19 Feb 1996Globaltrust Bank Ltd₹10 CrOpen
20 Dec 1995Global Trust Bank Ltd₹5 CrOpen
04 Dec 1995Global Trust Bank Ltd₹2.6 CrOpen
06 Jul 1995Global Tust Bank Ltd₹5.5 CrOpen

Total charge records: 95 View all charges

Deals & Funding

Dr.Reddy's Laboratories Ltd has 72 deals on record (61 market trades, 4 secondary share transfers, 4 acquisitions), with disclosed funding of ₹630 Cr; the latest was in September 2025.

Total deals
72
Market trades
61
Secondary share transfers
4
Acquisitions
4
Funding rounds
2
Disclosed funding
₹630 Cr

Deals on record (5 of 72)

WhenDealAmountParties
Feb 2025Funding round₹30 CrInvestors: Go Digit General Insurance Limited
Mar 2023Acquisition₹275 CrBuyer: Eris Lifesciences Limited
Seller: Dr.Reddy's Laboratories Ltd
Jun 2022Acquisition₹98.3 CrBuyer: J B Chemicals and Pharmaceuticals Limited
Seller: Dr.Reddy's Laboratories Ltd
Feb 2022AcquisitionUndisclosedBuyer: Mankind Pharma Limited
Seller: Dr.Reddy's Laboratories Ltd
Oct 2018AcquisitionUndisclosedBuyer: Therapiva Private Limited
Seller: Dr.Reddy's Laboratories Ltd

Full deal history: available in the company report

Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.

MSME Payment Delays

Dr.Reddy's Laboratories Ltd has 102 MSME Form 1 returns on record between 2008 and 2024, listing 879 overdue payments to 93 micro and small suppliers. Companies must report dues to micro and small suppliers that stay unpaid for more than 45 days in a half-yearly MSME Form 1 return.

Suppliers with reported dues (5 of 93)

SupplierAmount dueDue sinceReported on
Shree Anantaa Inc••••••••••••
Dasha Pharmaceuticals Private Limited••••••••••••
Sekhmet Technologies Private Limited••••••••••••
Agile Infrastructure••••••••••••
Chemic Life Sciences Private Limited••••••••••••

Full MSME payment history: available in the company report

Individuals and sole proprietors among the suppliers are not named. Amounts, due dates and filing dates are in the company report.

Employees and EPFO Compliance

Dr.Reddy's Laboratories Ltd has a workforce of 7,985 employees as of Nov 14, 2024.

Employee count
7,985
Active EPFO establishments
3
Employee growth
7.14%

Employee and EPFO history: available in the company report

Group Structure

Dr.Reddy's Laboratories has 9 subsidiary companies and 1 joint venture. This group structure data is as of FY 2022. The table lists each entity with its relationship and holding.

9
Subsidiary companies
1
Joint ventures
Key Subsidiaries
Company NameCINShares Held
Imperial Credit Private LimitedU06519TG1991PTC126383-
Aurigene Discovery Technologies LimitedU24239KA2001PLC029391-
Dr. Reddys Formulations LimitedU24299TG2021PLC149527-
Drl Impex LimitedU65990TG1986PLC006695-
Cheminor Investments LimitedU67120TG1990PLC010931-
Dr. Reddys Bio-Sciences LimitedU72200TG2000PLC034765-

Showing major subsidiaries. Total: 9.

Recent Activity

Dr.Reddy's Laboratories Ltd has 34 board changes on record since 1986: 13 appointments and 21 cessations. The latest: Srikanth Velamakanni was appointed as Additional Director on 01 Jul 2026.

AGM
Dr.Reddy'S Laboratories Ltd last Annual general meeting of members was held on 23 Jul 2026 as per latest MCA records.
Appointed
Srikanth Velamakanni was appointed as Additional Director.
Filing
Dr.Reddy'S Laboratories Ltd has filed its annual Financial statements for the year ended 31 Mar 2026 with Roc Hyderabad.
Appointed
Venkatanarasimham Mannam was appointed as CFO.
Appointed
Sanjiv Soshil Mehta was appointed as Director.
Appointed
Alpna Hansraj Seth was appointed as Director.
Appointed
Claudio Dr Albrecht was appointed as Director.
Appointed
Arun Madhavan Kumar was appointed as Director.
Ceased
Bruce Leonard Andrews Carter ceased to be Director.
Ceased
Parag Agarwal ceased to be Nodal Officer.
Appointed
Penny Chan Wan was appointed as Director.
Appointed
Kodumudi Pranatharthiharan Krishnan was appointed as Director.

237 earlier events are listed in the company report.

Credit Ratings, Litigation & Regulatory Alerts

Credit ratings, litigation, and regulatory alerts: available in the company report

Subsidiaries & Group Companies

Corporate group structure: available in the company report

GST Compliance

Dr.Reddy's Laboratories has 35 GST registrations: 24 active and 11 cancelled or inactive. The first 4 active GSTINs are listed below.

Total GSTINs
35
Active
24
Cancelled / inactive
11
GSTINStateStatusRegistered on
36AAACD7999Q1ZLTelanganaActive01 Jul 2017
36AAACD7999Q2ZKTelanganaActive19 Jul 2017
02AAACD7999Q1ZWHimachal PradeshActive01 Jul 2017
03AAACD7999Q1ZUPunjabActive01 Jul 2017

GST registrations and filing compliance: available in the company report

MCA Filings & Documents

MCA filings and documents: available in the company report

Related news

Dr. Reddy's Laboratories: Co Gets DCGI Approval For Zytorvi® (Toripalimab) For Advanced Esophageal Squamous Cell Carcinoma; This Marks The Second Approved Use In India, Expanding Beyond Nasopharyngeal Carcinoma; Clinical Trials Indicate A 42% Decrease In Risk Of Disease Or Death.
21 Oct 2026 · Exchange Update
DRREDDY: Rs. 24.65 Crores NSE Block Trade; for ~ 202,198 Shares, at Rs. 1219.00
30 Sep 2026 · Exchange Update
Dr. Reddy's Laboratories: Co CFO Is Sure About "High-Teen" Revenue Growth For FY27 And Later; The Company Has The Ability To Acquire Up To $2B In "Strategic Assets" And Is Aiming To Buy Firms And Brands Across Various Therapies.
29 Sep 2026 · Exchange Update
Dr Reddy's: CFO Expresses Interest In Acquiring Any Size Of Companies, Emphasizing The Importance Of The Right Assets.
29 Sep 2026 · Exchange Update
Dr. Reddy's Laboratories: Unveils New Products To Boost Growth; Targets 25% EBITDA Margin Long-Term And 20% For FY27.
29 Sep 2026 · Exchange Update
Dr Reddy's: Company's Co CFO Highlights Plans to Submit New PDT Applications in Emerging Markets; Nicotine Products Expected to Boost Sales in Europe by FY27.
29 Sep 2026 · Exchange Update

From our blog

Frequently Asked Questions

Dr.Reddy's Laboratories is an active public limited company based in Hyderabad, Telangana, India. The company works in drug formulation and development, within the pharma industry. It was incorporated on 24 February 1984 (42+ years old) and is registered under CIN L85195TG1984PLC004507. Listed on BSE: 500124 and NSE: DRREDDY.

Dr.Reddy's Laboratories reported revenue of ₹33,700 Cr for FY 2025-26 (up 3.2% YoY) based on consolidated financials.

Dr.Reddy's Laboratories has 13 current directors and KMP:

The latest financial statements of Dr.Reddy's Laboratories on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 23 July 2026. Year-wise statements from 2015 are in the company report.

The GSTIN of Dr.Reddy's Laboratories is 36AAACD7999Q1ZL, registered in Telangana. The company has 35 GST registrations in all, of which 24 are active and 11 are cancelled or inactive. Other active GSTINs include 36AAACD7999Q2ZK (Telangana), 02AAACD7999Q1ZW (Himachal Pradesh), 03AAACD7999Q1ZU (Punjab).

The CIN (Corporate Identification Number) of Dr.Reddy's Laboratories is L85195TG1984PLC004507. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.

Yes. Dr.Reddy's Laboratories is listed on both BSE (code: 500124) and NSE (symbol: DRREDDY).

Dr.Reddy's Laboratories has 730 court cases on record: 485 filed by the company and 247 filed against it. 192 are pending. Most are in the high courts.

Dr.Reddy's Laboratories was incorporated on 24 February 1984, making it 42+ years old. It is registered with the Registrar of Companies, Hyderabad.

Dr.Reddy's Laboratories has 72 deals on record (61 market trades, 4 secondary share transfers, 4 acquisitions), with disclosed funding of ₹630 Cr; the latest was in September 2025.

The peers of Dr.Reddy's Laboratories by revenue are Sun Pharmaceutical Industries Limited, Aurobindo Pharma Ltd, Cipla Limited, Zydus Lifesciences Limited, Lupin Limited and 1 more, all in the Pharma industry (Formulations), with the same principal business activity (chemical and chemical products, pharmaceuticals, medicinal chemical and botanical products).

Srikanth Velamakanni was appointed as Additional Director on 01 Jul 2026. Venkatanarasimham Mannam was appointed as CFO on 01 Aug 2024. Sanjiv Soshil Mehta was appointed as Director on 29 Dec 2023. Dr.Reddy's Laboratories has 34 board changes on record in total.

7M+ Indian companies. One platform.

Financials, directors, compliance, charges and shareholding - compiled from official filings and updated regularly.

Subscription plans available